Operating Segments (Tables)

9 Months Ended

Sep. 30, 2013

Operating Segments [Abstract]

Summary of segmental information

	Three Months Ended September 30,
	2013			2012
Revenues, Principally from Grants
Vaccines/BioDefense	$	264,920		$	862,919
BioTherapeutics		47,571			68,708
Total	$	312,491		$	931,627
Loss from Operations
Vaccines/BioDefense	$	(419,929	)	$	19,190
BioTherapeutics		(1,080,436	)		(155,713	)
Corporate		(360,297	)		(623,693	)
Total	$	(1,860,662	)	$	(760,216	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	28,316		$	31,357
BioTherapeutics		29,233			32,180
Corporate		551			495
Total	$	58,100		$	64,032
Other Income /(Expense), Net
Corporate	$	(4,699,194	)	$	1,250
Stock-Based Compensation
Vaccines/BioDefense	$	39,493		$	29,103
BioTherapeutics		158,142			(49,275	)
Corporate		209,256			167,944
Total	$	406,891		$	147,772

	Nine Months Ended September 30,
	2013			2012
Revenues, Principally from Grants
Vaccines/BioDefense	$	1,683,265		$	2,170,761
BioTherapeutics		161,858			171,135
Total	$	1,845,123		$	2,341,896
Income (Loss) from Operations
Vaccines/BioDefense	$	(1,983,396	)	$	(111,319	)
BioTherapeutics		(2,068,703	)		(1,363,572	)
Corporate		(1,652,344	)		(1,707,992	)
Total	$	(5,704,443	)	$	(3,182,883	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	83,951		$	84,308
BioTherapeutics		86,303			86,913
Corporate		1,412			1,564
Total	$	171,666		$	172,785
Other Income /(Expense), Net
Corporate	$	(5,347,984	)	$	5,284
Stock-Based Compensation
Vaccines/BioDefense	$	61,742		$	33,363
BioTherapeutics		205,083			63,339
Corporate		304,346			286,072
Total	$	571,171		$	382,774

	As of September 30,  2013		As of December 31, 2012
Identifiable Assets
Vaccines/BioDefense	$	442,407	$	628,494
BioTherapeutics		411,847		566,111
Corporate		6,795,793		3,510,499
Total	$	7,650,047	$	4,705,104